Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 26, 1998

View Archived Issues

Laminin-related polypeptides from the University of Minnesota

Matritech receives SBIR grant for cancer test development

SS Pharm. describes new triazoles with oral activity

Squalene synthase inhibitors patented by Pfizer

Imidazoles for reversing MDR prepared at Ontogen

Dual 5-HT reuptake inhibitors/5-HT1A antagonists developed at Lilly

Virus-host cell fusion inhibitors under study at Lilly

Agents for schizophrenia without EPS disclosed by Warner-Lambert

New heterocyclic bradykinin antagonists from Fujisawa

Ortho reveals new fibrinogen receptor antagonists

Two NDAs up for review this week by Cardiovascular and Renal Drugs Advisory Committee

Neuroprotective effects of new PARS inhibitor

European alliance formed by Faulding and Asta Medica

Theratechnologies' novel cancer treatment granted additional patent protection

ProstaScint may predict response of prostate cancer patients to salvage radiotherapy

Clinical trial status of pain control implant updated by CytoTherapeutics/Astra

Expansion of Advanced Tissues Sciences/Smith & Nephew joint venture planned

Pfizer updates development pipeline

Nabi's Altastaph enters phase I/II

Additional data submitted to FDA to support Novastan NDA

Atherosclerosis program at Genome Therapeutics expanded

Adenosine metabolism inhibitor research at Cypros supported by grant

Randomized trial compares interferon alfa-2b + ribavirin to interferon alone for HCV

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...